期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

80岁及以上晚期非小细胞肺癌患者一线化疗的临床观察 被引量：4

下载PDF
导出
摘要 随着肺癌发病率的上升以及人口的老龄化，老年肺癌患者的人数也相应增加。已有的关于老年非小细胞肺癌化疗的临床研究，选择的多数是80岁以下的患者，80岁及以上的非小细胞肺癌患者，主要脏器功能往往相对低下，合并症较多，为了更多了解这部分患者化疗的疗效及耐受性，本文分析了80岁及以上有较好体力状态和脏器功能，无EGFR基因突变或基因突变不详的晚期非小细胞肺癌一线单药化疗的临床资料，现报告如下。
作者 张萍 武晓楠 艾斌 聂鑫 李琳 程刚
机构地区 卫生部北京医院肿瘤科
出处 《中国临床保健杂志》 CAS 2012年第5期538-539,共2页 Chinese Journal of Clinical Healthcare
关键词 晚期非小细胞肺癌 肺癌患者 单药化疗 临床观察 老年非小细胞肺癌 脏器功能 基因突变 癌发病率
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients : An analysis of the surveillance, epide- miology, and end resuhs database [ J ]. J Clin Oncol, 2007,25 ( 35 ) :5570-5577.
  • 2Ahundaq O, Stewart DJ, Fossella FV, et al. Many patients 80 years and older with advanced non-small cell lung cancer(NSCLC) can tolerate chemotherapy [ J ]. J Thorac Onco1,2007,2 ( 2 ) : 141-146.
  • 3Weiss J, Stinchcombe TE. Treatment of elderly patients with stage Ⅳ non-small cell lung cancer [ J ]. Expert Rev Anticancer Ther,2012,12( 1 ) : 111-120.
  • 4Earle CC, Tsai JS, Gelber RD, et al, Effectiveness of chemotherapy for advanced lung cancer in the elderly:in- strumental variable and propensity analysis [ J ]. J Clin Oneo1,2001,19(4) : 1064-1065.
  • 5Hesketh PJ, Lilenbaum RC, Chansky K, et al. Chemother- apy in patients > or = 80 with advanced non-small cell lung cancer : combined results from SWOG 0027 and LUN 6[ J]. J Thorac 0ncol,2007,2(6):494-498.
  • 6Fisher MD, D' Orazio A. Phase Ⅱ and Ⅲ trials : compari- son of four chemotherapy regimens in advanced non small cell lung cancer (ECOG 1594) [ J ]. Clin Lung Cancer, 2000,2 (1) :21-22.
  • 7Ganti AK, Deshazo M, Weir AB, et, al. Treatment of non- small cell lung cancer in the older patient [ J ]. J Natl Compr Canc Netw,2012,10 (2) : 230-239.
  • 8Langer CJ,Vangel M,Schiller J ,et al. Age-specific sub-a- nalysis of ECOG 1594 : Fit elderly patients ( 70-80 years) with NSCLC do as well as younger patients ( < 70) [ J ]. Proc Am Soc Clin 0ncol,2003,22(3) :639.
  • 9刘鹏,冯奉仪,石远凯.老年晚期非小细胞肺癌化疗的临床分析(附29例报告)[J].北京医学,2009,31(9):523-525. 被引量：1

二级参考文献14

  • 1Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol, 2001,29:533-43.
  • 2Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small cell lung cancer? Lung Cancer, 2002,38(Suppl):S45-S50.
  • 3Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 2003,95:341-343.
  • 4Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review 1975 - 2000. J Nail Cancer Inst, 2003,95:1276-1299.
  • 5Montella M, Gridelli C, Crispo A, et al. Has lung cancer in the elderly different characteristics at presentation. Oncol Rep, 2002,9: 1093-1096.
  • 6Gridelli C, Cigolari S, Gallo C, gemcitabine and gemcitabine et al. Activity and toxicity of + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer, 2001,31:277-284.
  • 7Balducci L. Management of cancer in the elderly. Oncology, 2006,20:135-152.
  • 8Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer:, a Southwest Oncology Group trial. J Clin Oncol,2001,19:3210-3218.
  • 9Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med,2002,346:92-98.
  • 10Firvida JL, Amenedo M, Rodriguez R,et al. Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer:results of a phase II study. Invest New Drugs, 2004,22:481-487.

同被引文献36

  • 1李民,张利萍,吴新民.右美托咪啶在临床麻醉中应用的研究进展[J].中国临床药理学杂志,2007,23(6):466-470. 被引量：483
  • 2Gazzeri S.P53 genetic abnormalities and mycactivati on in human lung carcinoma. Int J Cancer, 1994, 58(1):24-32.
  • 3Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional ass-ociation between WWOX tumorsuppressor protein and p73, a P53 homolog. Proc NatlAcad Sci USA, 2004, 101(13):4401-4406.
  • 4Ludes-Meyers JH, KiI H, Bednarek AK, et al. WWOX binds the specific proline-rich ligand PPXY: identificati on of can-didate interacting proteins. J Oncogene, 2004, 23(29): 5049-5055.
  • 5Palakodeti A, Han Y, Jiang Y, et al. The role of late/slow replication ofFP, A16D in common fragile site induction. Genes Chromosomes Cancer, 2004, 39(1):71-76.
  • 6Donati V, Fonta nini G , Dell-Omodarme M, et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. J Clin Cancer Res, 2007, 13(3): 884-891.
  • 7Kraemer-Pecore CM, Lecomte JT, Desjarlais JR. A denovo redesign of the WWOX domain. Protein Sci, 2003, 12(10):2194-2205.
  • 8Nunez MI, Ludes-Mevers J, Abba MC, et al. Frequem loss of WWOX expression in breast cancer:correlation with estrogen receptor status. J Breast Cancer Res Treat, 2005, 89:99-105.
  • 9Fabbri M, lliopoulos D, Trapasso F, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. PNAS, 2005, 102(43): 15611 - 15616.
  • 10Voepel-Lewis T,Malviya S,Tait A R. A prospective cohort study of emergence agitation in the pediatric postanesthesia care unit. Anesthesia \& Analgesia,2003,96(6):1625-1630.

引证文献4

二级引证文献26

中国临床保健杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部